GlaxoSmithKline (NYSE: GSK) reported Q3 EPS of GBP0.47, versus the analyst estimate of GBP0.93. Revenue for the quarter came in at GBP7.8 billion versus the consensus estimate of GBP8.24 billion.

GUIDANCE:

2022 Guidance raised: expect to deliver growth in sales of between 8% to 10% CER and growth in 2022 adjusted operating profit of between 15% to 17% CER.

For earnings history and earnings-related data on GlaxoSmithKline (GSK) click here.